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Lung Cancer Care Before and After  
Medicare Eligibility
Marco D. Huesch, MBBS, PhD1 and Michael K. Ong, MD, PhD2,3
Abstract
Uninsured and underinsured near-elderly may not have timely investigation, diagnosis, or care of cancer. Prior studies suggest 
Medicare eligibility confers significant and substantial reductions in mortality and increases in health service utilization. We 
compared 2245 patients diagnosed with lung cancer at ages 64.5 to 65 years and 2512 patients aged 65 to 65.5 years, with 
2492 patients aged 65.5 to 66 years (controls) in 2000 to 2005. Compared with controls, patients diagnosed with lung cancer 
before Medicare eligibility had no statistically significant differences in cancer stage, time to treatment, type of treatment, and 
survival. Study power was sufficient to exclude mortality reductions and health service utilization changes of the magnitude 
found in prior work, suggesting that typically, appropriate lung cancer care may be sought and delivered regardless of 
insurance status.
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Introduction
There is broad agreement that health insurance coverage is 
generally associated with better health outcomes and with 
receipt of appropriate care.1-3 Access to care and some out-
comes were better with lower co-pays in the Health Insurance 
Experiment.4 Losing and continuing not to have health insur-
ance has been associated with declines in overall health.5-8
Yet there is less evidence for this in the near-elderly.9-11 If 
subsidizing and extending coverage to these patients yields 
better and more cost-effective outcomes, making such 
transfer payments may make good policy. While the 
Affordable Care Act is likely to cover many previously unin-
sured people with subsidized private coverage in state insur-
ance exchanges,12 some states may reject the Medicaid 
expansion options.13
Some have looked at differences in health before and after 
the age of 65 years. Before this age, there are many unin-
sured and underinsured.6 It is estimated that 13% of the near-
elderly in the 55 to 64 years age group are uninsured.14 
Additional large numbers of patients are underinsured 
patients with less generous (eg, high deductible individual 
policies) or less widely accepted means-tested public insur-
ance such as Medicaid.15
After age 65 years, nearly all are eligible for universal 
insurance under Medicare. Improvement and increases in 
health,16 services use,17 self-reports of health,18 disease con-
trol,19 and survival after acute conditions have been 
reported.15
The magnitude of estimated improvements is strikingly 
large. Card et al15 found a 20% relative reduction in deaths 
for severely ill patients treated urgently immediately after the 
age of 65 years, compared with similar patients treated 
immediately before the age of 65 years, a mortality gap that 
persisted for at least 9 months after the index admission. 
Similarly, large relative increases of between 11% and 23% 
in nonurgent medical procedures were found in those above 
65 years compared with those below 65 years.18
However, the complex methods used in some investiga-
tions have sparked debate about the true existence of benefi-
cial effects16,20,21 and the interpretation of results.7,20,22
Others have not found any relative slowing of health 
decline after 65 years among the previously uninsured,20 nor 
any population mortality impact in the 10 years following 
Medicare enactment.23 These discrepant findings may in part 
be due to different types of health conditions studied. Still 
others point to the risk that generous insurance may lead to 
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patient moral hazard,24 which could cause patient harms 
through overdetection, overdiagnosis, or even overtreatment 
of disease.
It has been argued that Medicare’s insurance effects could 
also lead to differences in outcomes and costs among cases 
of common, serious cancers diagnosed around the 65th year 
of age.25 In this study, we examine lung cancer and seek to 
understand whether the magnitude of beneficial insurance 
effects is as high as suggested by the prior literature.15,18
Our objective is to understand these potential associations 
and we examined staging, treatment and outcomes for 
patients diagnosed before and after Medicare eligibility 
among US patients.
Conceptual Framework
Lung cancer is typically a fast progressing cancer after diag-
nosis and leads to more deaths in the United States than any 
other type of cancer.26 Among patients with a lethal cancer 
such as lung cancer, insurance status may be associated with 
outcomes and costs in 2 ways.
First, patients may receive a lung cancer diagnosis before 
they are eligible for Medicare. They may then face delays in 
receiving appropriate disease-specific and stage-specific 
care until they are eligible for Medicare. Such patients may 
then face significantly longer treatment delays, different 
treatment, or different outcomes than patients diagnosed 
considerably later, after Medicare eligibility.
Second, patients may face delays in investigation of the 
symptoms and signs of lung cancer before they are eligible 
for Medicare. They may then not have a diagnosis made until 
they are newly eligible for Medicare. These patients may 
then have significantly more advanced disease, different 
treatment, or different outcomes than patients diagnosed 
later after Medicare eligibility.
Data and Methods
We analyzed a national convenience sample, the 
Surveillance, Epidemiology, and End Results (SEER) 
registry data maintained by the National Cancer Institute 
(NCI).27 Due to differences in course of disease, we con-
structed different sized analytical cohorts for the 2 different 
cancers (Figure 2). The NCI administers 15 SEER registries, 
which cover approximately 26% of the national popula-
tion.28 We used the Patient Entitlement and Diagnosis 
Summary File (PEDSF) files, which link SEER registry data 
with Centers for Medicare & Medicaid Services’ master 
enrollment file data.29
The PEDSF file contains each patient’s month and year of 
birth, date of death (if any), sex, marital status, race, ethnic-
ity, state of residence, Census Bureau data on basic socioeco-
nomic status at the census tract and zip code level, reason for 
Medicare entitlement, and Medicare Part A, B, or C enroll-
ment. Diagnosis information contains site, grade, extent of 
disease, staging, and manner of confirmation. Treatment 
information is available for month and year of treatment with 
radiation, and for cancer-directed surgery.30
We obtained all SEER-Medicare PEDSF files for lung 
cancer patient diagnoses made between 2000 through 2005. 
The linked Centers for Medicare and Medicaid Services 
(CMS) data in the PEDSF files allowed vital statistics fol-
low-up through the end of 2007. We included SEER-
Medicare patients with a diagnosis of lung or bronchus 
cancer (SEER 2-digit site recode 39). We excluded patients 
whose lung or bronchus cancer diagnosis was not the first in 
the SEER registries as patient characteristics and physician 
behavior may be systematically different in patients with a 
second occurrence of cancer. We excluded patients with 
missing or invalid data for diagnosis month and/or year and 
patients eligible for Medicare on the basis of disability or 
end-stage renal disease.
We used birth month and year and diagnosis month and 
year to create age-specific cohorts from the total of 7249 
patients who met our inclusion criteria (Figure 1). We con-
structed a cohort of 2245 patients aged 64.5 to 65 years 
(which we refer to as “pre-eligible”), a cohort of 2512 
patients aged 65 to 65.5 years (“newly eligible”), and a con-
trol cohort of 2492 patients aged 65.5 to 66 years (“control 
eligible”) at time of diagnosis.
Figure 1. Cohorts and frequency of cases by cancer type, age, and eligibility.
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For baseline cohort characteristics, we present frequen-
cies for categorical variables and means with standard devia-
tions for continuous variables. We tested the significance of 
changes in categorical (stage, diagnostic confirmation) and 
ordinal (tumor size) variables using chi-square tests. We used 
Kruskal-Wallis equality of populations tests for changes in 
continuous variables and median tests for equality of medi-
ans. For diagnostic categorical variables, we present fre-
quencies in each cohort. We collapsed diagnoses of small 
cell lung cancer into 1 category. We also collapsed diagnoses 
of stage I and stage II non-small cell lung cancer into 1 cat-
egory, and cases of stage III and stage IV non-small cell lung 
cancer into another category.
For outcome variables, we present frequencies and unad-
justed risks in each cohort. We compared proportions surviv-
ing 0, 3, 6, 12, and 24 months and proportions receiving 
initial cancer-directed therapy within 0, 1, 2, 3, 4, 6, and 12 
months of diagnosis using chi-square tests of crude risk 
ratios. Separately we compared the proportions of patients 
receiving radiation and/or surgery for patients in whom ther-
apy was started within 4 months of diagnosis. We had data 
through December 31, 2007, or at least 24 full months fol-
lowing diagnosis, allowing event rates to be calculated for all 
patients.
Our data were interval censored at the month level. For 
outcome proportions and rates, we treated an outcome occur-
ring in the same month as diagnosis as occurring at month 0, 
though this may have happened from 0 to 61 days after 
diagnosis. We maintained the assumption that over any time 
period this bias was mean zero and not differential over the 
cohorts under comparison. In our 12- and 24-month out-
comes data, the possible magnitude of this bias is small in 
relative terms.
In event history analyses, we plot crude rates of outcomes 
and rates adjusted for competing risks.31,32 We used Kaplan-
Meier graphs to plot cumulative failure for the outcomes of 
receipt of radiation or cancer-directed surgery, and for the 
outcomes of death from all causes and death from lung can-
cer alone. Survival from all causes and treatment data was 
treated as censored after December 31, 2007. Survival from 
lung cancer alone was treated as censored after December 
31, 2006, the latest death certificate follow-up in the SEER 
data. We used the log-rank test to compare failure distribu-
tions across cohorts in analyses not adjusting for competing 
risks.
Our Kaplan-Meier plots for survival, survival from lung 
cancer, and receipt of treatment assume that earlier death 
from other causes is not informative. This does not ade-
quately adjust for competing risks.33,34 In lung cancer treat-
ment, decisions and survival are unlikely to be conditionally 
independent, given patient characteristics. In the older 
cohorts, we need to take into account an increased risk of 
death from other causes. We used cumulative incidence 
graphs to analyze treatment receipt, adjusted for the compet-
ing risk of death from any cause. We also plotted the cumula-
tive incidence for death from the primary cancer diagnosis, 
Figure 2. Cumulative incidence for therapy start, adjusted for death as competing risk, for pre-Medicare eligible (64.5-65 years old) and 
control cohorts (65.5-66 years old).
Note. SEER = Surveillance, Epidemiology, and End Results; OASI = Old Age Survivors Insurance.
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adjusted for the competing risk of death from any other 
known cause.
SEER*Medicare data35 were managed using SAS soft-
ware, version 9.2; all statistical computations and graphical 
output were performed using Stata/SE software, version 
10.1. All analyses were 2-tailed. No adjustments for multiple 
comparisons were made.36 We considered all P values less 
than .05 to be statistically significant. This study was 
approved by the institutional review board (IRB) of the study 
institution’s Health System and declared exempt from IRB 
review under 45CFR46.101(b)(4).
Results
Baseline characteristics generally did not differ signifi-
cantly across the pre-Medicare eligible, newly eligible, or 
eligible cohorts (Table 1). Gender, ethnicity and race, resi-
dence in metropolitan areas, and marital status were simi-
lar across cohorts. There was a small but significant 
difference in the extent of poverty in the patient residence 
census tracts across age cohorts (P < .001). This may rep-
resent artifactual variation or changes in residence after 
retirement.
Diagnostic characteristics were not significantly different 
in extent of disease, staging, and manner of diagnostic con-
firmation (Table 2). Across the pre-eligibility, newly eligible, 
and eligible cohorts, there was no consistent or significant 
trend in staging.
The rate of lung cancer diagnosis based on death certifi-
cate only, without evidence of clinical, imaging, or patho-
logical conformation was constant and low across the 
cohorts. Among the pre-eligible cohort, 95.1% of patients 
had lung cancer confirmed on pathology. In newly eligible 
Medicare patients, this rate was 94.7%, and in patients 
already eligible for Medicare for at least 6 months, it was 
94.9% (P = .62).
Treatment receipt exhibited no significant differences 
across cohorts in timing or type of treatment (Table 3). Of the 
pre-eligible cohort, 78.0% received therapy within 4 months 
as did 78.5% of the newly eligible, compared with 78.4% of 
the 65.5 to 66 years old cohort. Unadjusted risk ratios did not 
differ significantly from equality and were not significant 
when comparing pre-eligible and control cohorts, or when 
comparing newly eligible and control cohorts.
At this 4-month landmark, radiation and/or cancer-
directed surgery receipt did not differ across the cohorts.
Treatment event history over time was not different 
with the hazard of receiving initial cancer-directed therapy 
identical across cohorts, ignoring the competing risk of 
death (unreported). Nearly 75% of registry patients had 
started a cancer-directed therapy within 2 months, with no 
difference between the pre-eligible and the control cohorts 
Table 1. Lung Cancer Characteristics of Pre-Medicare Eligible, Newly Eligible, and Post-Medicare Eligible Cohorts.
Age at diagnosis, y
No. (%)
P value
Pre-eligibility cohort Newly eligible cohort
Eligible for Medicare 
cohort
64.5-65 (n = 2245) 65-65.5 (n = 2512) 65.5-66 (n = 2492)
Age at diagnosis, mean (SD), y 64.8 (0.14) 65.3 (0.14) 65.8 (0.14) <.001
Male 1203 (53.6) 1356 (54.0) 1364 (54.7) .72
Caucasian 1825 (81.3) 2060 (82.0) 2016 (80.9) .74
African American 201 (9.0) 231 (9.2) 217 (8.7)
Asian American 108 (4.8) 99 (3.9) 122 (4.9)
Hispanic 95 (4.2) 108 (4.3) 120 (4.8)
Other or unknown 16 (0.7) 14 (0.6) 17 (0.7)
Big metro 1322 (58.9) 1478 (58.8) 1492 (59.9) .15
Never married 255 (11.4) 273 (10.9) 246 (9.9) .45
Married 1327 (59.1) 1513 (60.2) 1493 (59.9)
Separated 27 (1.2) 22 (0.9) 30 (1.2)
Divorced 309 (13.8) 323 (12.9) 317 (12.7)
Widowed 233 (10.4) 285 (11.3) 307 (12.3)
Unknown marital status 94 (4.2) 96 (3.8) 99 (4.0)  
Census tract variables, medians
 Median income, $ 45 095 44 272 45 108 .15
 4+ years college education, % 19.6 19.1 19.2 .85
 <Poverty level, age and race 
specific, %
7.6 5.1 4.7 <.001
Note. Big metro = counties in metropolitan areas of 1 million or more population.
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(P = .79). Similar nonsignificant estimates were found for 
the comparison between the newly eligible and the control 
cohorts.
In analyses that were robust to the competing risk of 
death, cumulative incidence for treatment receipt showed 
no essential differences for the comparison of pre-eligible 
and control cohorts (Figure 2) as well as for the comparison 
of newly eligible and control cohorts (unreported).
Turning to longer term survival (Table 3), point estimates 
of death rates were consistent with small secular increase 
over age across the cohorts. The pre-eligible cohort unad-
justed rate of death was 36.4% within 6 months, compared 
with 36.7% for 65.5 to 66 years old control cohort (crude risk 
ratio 0.99; P = .86).
A total of 36.2% of newly Medicare-eligible patients with 
lung cancer died within 6 months of diagnosis, indistinguish-
able from the control cohort (crude risk ratio 0.99; P = .72). 
Survival event history showed no significant cohort differ-
ences (not reported). Kaplan-Meier complements for overall 
survival overestimate death due to lung cancer, since they do 
not differentiate between death due to lung cancer and death 
to other causes.
Cumulative incidence estimates that adjust for the com-
peting risk of death from other causes (Figure 3) show the 
older control cohorts having statistically identical incidence 
of lung cancer specific deaths, but slightly higher incidence 
of other deaths as would be expected given the secular trend 
in mortality hazard.
Table 2. Lung Cancer, Extent of Disease, Staging, and Method of Diagnostic Confirmation.
Age at diagnosis, y
No. (%)
P value
Pre-eligibility cohort Newly eligible cohort
Eligible for Medicare 
cohort
64.5-65 (n = 2245) 65-65.5 (n = 2512) 65.5-66 (n = 2492)
Extent of disease, 2000-2003
 Size of tumor, median, mm 40 40 39 .97
Tumor extent
 One lung 264 (17.1) 323 (19.0) 315 (18.5) .37
 Metastatic 571 (37.0) 629 (36.9) 633 (37.1) 1.00
Lymph node involvement
 None 436 (28.3) 484 (28.4) 491 (28.8) .95
 Mediastinal 498 (32.3) 549 (32.2) 555 (32.5) .98
 Contralateral or distant 169 (11.0) 181 (10.6) 166 (9.7) .49
Staging, 2000-2003
 Small-cell, any stage 268 (17.4) 248 (14.6) 255 (14.9) .33
 Non-small cell, stage I/II 230 (14.9) 287 (16.9) 279 (16.3)
 Non-small cell, stage III/IV 814 (52.8) 909 (53.4) 913 (53.5)
 Unstaged 231 (15.0) 259 (15.2) 260 (15.2)
Staging, 2004-2005
 Small-cell, any stage 107 (15.2) 105 (13.0) 109 (13.9) .49
 Non-small cell, stage I/II 140 (19.9) 180 (22.3) 185 (23.6)
 Non-small cell, stage III/IV 398 (56.7) 455 (56.2) 417 (53.1)
 Unstaged 57 (8.1) 69 (8.5) 74 (9.4)
Staging, combining 2000-2005
 Small-cell, any stage 375 (16.7) 353 (14.1) 364 (14.6) .11
 Non-small cell, stage I/II 370 (16.5) 467 (18.6) 464 (18.6)
 Non-small cell, stage III/IV 1212 (54.0) 1364 (54.3) 1330 (53.4)
 Unstaged 288 (12.8) 328 (13.1) 334 (13.4)
Diagnostic confirmation
 Histological 1735 (77.3) 1977 (78.7) 1945 (78.1) .62
 Cytological 399 (17.8) 402 (16.0) 418 (16.8)
 Imaging only 60 (2.7) 75 (3.0) 65 (2.6)
 Clinical only 11 (0.5) 13 (0.5) 21 (0.8)
 Death certificate only 35 (1.6) 39 (1.6) 38 (1.5)
Note. Extent of disease based on the <e10sz1>, <e10ex1>, and <e10nd1> SEER data fields for cases in 2000 to 2003. Size excludes “diffuse.” Extent and 
lymph node involvement: 3 most common values each, except “unknown.” Staging of cases in 2000 to 2003 reflects SEER coding of AJCC (American Joint 
Committee on Cancer) stage field and in 2004 to 2005 reflects DAJCC (Derived AJCC) stage field. SEER = Surveillance, Epidemiology, and End Results.
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We considered three potential threats to the robustness of 
our results. These hinged around (1) adequacy of the study’s 
power, whether (2) inclusion in the study was biased by 
potential nonrandom missingness, and whether (3) the diag-
nostic threshold for lung cancer was constant. We report in 
the Appendix that our results appeared robust to these poten-
tial threats.
Conclusions
This study used cancer registry data to detail disease, treat-
ment, and outcome differences among the near-elderly and 
elderly around the age of 65 years for a common and impor-
tant cancer. Our approach was designed to identify harms 
from underinsurance and benefits from insurance due to bet-
ter and more timely access to care. Nevertheless, our study 
failed to show substantial, consistent, or clinically meaning-
ful differences between patients diagnosed before and imme-
diately after eligibility for Medicare.
In this large, nation-wide study using recent lung cancer 
data, we found no clinically meaningful evidence that under-
insurance or uninsurance harmed patients diagnosed with 
lung cancer before Medicare eligibility. We found minor but 
insignificant differences in lung cancer stage. However, in 
time to treatment, in treatment type, in lung cancer–specific 
survival, and in all-cause survival, no significant differences 
were found across cohorts.
Our study was premised on discontinuous change in 
insurance status caused by exogenous aging into Medicare at 
age 65 years. Before this age, there are large numbers of 
uninsured patients6,37 with an estimated 13% of the near-
elderly in the 55 to 64 years age group uninsured.14 Pre-
Medicare eligibility, many other individuals are underinsured 
due to less generous (eg, high deductible individual policies) 
or less widely accepted insurance (eg, Medicaid).
Improved access to insurance has been found to be associ-
ated with better access to health care and improvement in 
health,16,17 with substantially improved survival after acute 
conditions,15 and with substantially increased utilization of 
care.16-18,38 Yet this adequately powered study was unable to 
detect differences in survival or utilization of the magnitude 
found by prior studies.
Our study has several important limitations that remain 
unresolved despite extensive robustness checks. Our study 
focuses narrowly on 1 type of cancer, albeit a common, well-
known and important one. Our data are not necessarily rep-
resentative of the entire US population. Currently, the SEER 
databases cover approximately 26% of the total US 
Table 3. Lung Cancer, Time to Initial Therapy, Type of Therapy Received, and Deaths, Crude and Not Adjusted for Competing Risks.
Age at diagnosis, y
No. (%)
Pre-eligibility 
cohort
Newly eligible 
cohort
Eligible for 
Medicare cohort
Crude risk ratio (95% confidence interval) of cohort vs 
65.5-66 y cohort
64.5-65  
(n = 2245)
65-65.5  
(n = 2512)
65.5-66  
(n = 2492)
Pre-eligibility 
cohort P value
Newly eligible 
cohort P value
Initial therapy started, mo
 0 725 (32.3) 788 (31.4) 817 (32.8) 0.99 (0.91-1.07) .72 0.96 (0.88-1.04) .28
 1 1447 (64.5) 1592 (63.4) 1582 (63.5) 1.02 (0.97-1.06) .49 1.00 (0.96-1.04) .94
 2 1649 (73.5) 1854 (73.8) 1822 (73.1) 1.00 (0.97-1.04) .79 1.01 (0.98-1.04) .58
 3 1729 (77.0) 1944 (77.4) 1918 (77.0) 1.00 (0.97-1.03) .97 1.01 (0.98-1.04) .72
 4 1752 (78.0) 1973 (78.5) 1954 (78.4) 1.00 (0.97-1.03) .76 1.00 (0.97-1.03) .91
 6 1772 (78.9) 1990 (79.2) 1976 (79.3) 1.00 (0.97-1.03) .76 1.00 (0.97-1.03) .95
 12 1788 (79.6) 2006 (79.9) 1987 (79.7) 1.00 (0.97-1.03) .94 1.00 (0.97-1.03) .91
Initial therapy received, ≤ 4 mo
 Radiation 976 (55.7) 1075 (54.5) 1029 (52.7) 1.06 (1.00-1.12) .06 1.03 (0.98-1.10) .25
 Cancer-directed surgery 594 (33.9) 736 (37.3) 706 (36.1) 0.94 (0.86-1.02) .16 1.03 (0.95-1.12) .45
 Both 169 (9.6) 197 (10.0) 166 (8.5) 1.14 (0.93-1.39) .22 1.18 (0.97-1.43) .11
 Neither 351 (20.0) 359 (18.2) 385 (19.7) 1.02 (0.89-1.16) .80 0.92 (0.81-1.05) .23
Death, mo
 0 116 (5.2) 134 (5.3) 129 (5.2) 1.00 (0.78-1.27) .99 1.03 (0.81-1.30) .80
 3 531 (23.7) 608 (24.2) 653 (26.2) 0.90 (0.82-1.00) .04 0.92 (0.84-1.02) .10
 6 818 (36.4) 909 (36.2) 914 (36.7) 0.99 (0.92-1.07) .86 0.99 (0.92-1.06) .72
 12 1207 (53.8) 1360 (54.1) 1365 (54.8) 0.98 (0.93-1.03) .49 0.99 (0.94-1.04) .65
 24 1565 (69.7) 1737 (69.1) 1725 (69.3) 1.01 (0.97-1.05) .74 1.00 (0.96-1.04) .93
Note. Events at 0 represent same month at diagnosis. Later events refer to events through end of the given month. “Neither” = initial therapy due to 
other (eg, chemotherapy).
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population in a nonrandom manner. For example, there is a 
large concentration of states in the West and Southwest 
(California, New Mexico, Arizona, and Utah) but far less or 
no representation in the rural Northeast and much of the large 
population centers in the Midwest apart from Iowa. 
Approximately 98% of cancer cases are ascertained in that 
population.39 Whether missing data in the cohorts we exam-
ined are missing at random is unknown.
Related to this limitation is our inability to compare and 
contrast variations in small areas of the relationship of insur-
ance coverage and treatment and outcomes. This is driven by 
the relatively low sample sizes at the individual state level, or 
the individual counties captured in some states. Our study’s 
statistical power is inadequate for such comparisons, even 
though it is possible that there are differences in profession-
alism among providers and hospitals by geography, and 
potential differences in access to care without concern about 
coverage and reimbursement.
Other limitations are that we included patients from the 
2000 calendar year, even though major registry expansion 
happened in 2000. We also pooled data across multiple calen-
dar years, ignoring possible cohort effects. We did not ascer-
tain the receipt of chemotherapy, which is separately coded in 
the Medicare claims for patients enrolled in fee-for-service 
Medicare.40 Information on cancer-directed surgery was lim-
ited to the most extensive procedure among planned 
procedure(s) performed for the primary cancer or surgery per-
formed within a year if cancer does not recur or progress.30 We 
do not observe whether treatment was curative, adjuvant, or 
palliative. If surgery to relieve metastatic disease differs sys-
tematically across cohorts, then we will miss such differences. 
We were also unable to quantify cohort treatment costs, which 
are important as cancer costs continue to rise.41
Other disease-specific limitations include the fact that this 
study took place in the period of time before the positive trial 
results on low-dose computed tomography (CT) screening 
for lung cancer.42 Our results might have been different in a 
later period in which screening was reduced. Our data also 
lack information on patient co-morbidities or preferences, 
which might drive differences in therapy afforded. However, 
rates of patients who did not undergo surgery that had been 
recommended did not differ significantly across the cohorts.
Our study fails to support concerns that patients diag-
nosed with lung cancer just before Medicare eligibility faced 
delays in receiving appropriate disease and stage-specific 
care until they are eligible for Medicare. These results are 
also not consistent with patients facing delays in investiga-
tion of the symptoms and signs of lung cancer before they are 
eligible for Medicare, with subsequently more advanced dis-
ease after Medicare eligibility.
There are a number of alternative explanations for our 
study’s negative results. For example, differences in care 
may exist, but their effects may be too small to detect. Given 
the adequate power in this study, and the prior literature 
results suggesting substantial changes in general, this expla-
nation may not be compelling.
Figure 3. Cumulative incidence of death from lung cancer and death from other causes for pre-Medicare eligible (64.5-65 years old) 
and control cohorts (65.5-66 years old).
Note. SEER = Surveillance, Epidemiology, and End Results.
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Another alternative explanation is that most patients with 
lung cancer present with a poor prognosis. Our failure to find 
differences in cancer care immediately pre-and post-Medi-
care eligibility may therefore simply reflect the natural his-
tory of this disease. This is plausible but mitigated somewhat 
by the persisting absence of differences even at 24 months’ 
follow-up of lung cancer. Finally, differences in cancer care 
due to reduced pre-Medicare access among the uninsured or 
underinsured may exist, but could be compensated for by 
physicians providing differential care to these upon eligibil-
ity. Our study could not identify such confounding, but can-
not rule this explanation out.
The simplest explanation for our results is also the most 
reassuring. Patients with serious diseases receive timely 
investigation, diagnosis, and treatment regardless of insur-
ance coverage. On the patient side, the symptoms and signs 
of undiagnosed lung cancer may lead a patient to seek inves-
tigation regardless of ability to pay. On the provider side, the 
seriousness of diagnosed lung cancer may ensure the provi-
sion of care to such patients regardless of ability to pay.
Even though we found no evidence of Medicare effects in 
an acute, serious disease, there may be unobserved improve-
ments in patient well-being. For example, access to health 
care may provide subjective improvements in stress. In lung 
cancer, the availability of expensive epidermal Growth 
Factor Receptor (eGFR) tyrosine kinase inhibitors such as 
erlotinib (Tarceva®) in 2005 coincides with the end of our 
sample period. Insurance coverage may have allowed 
patients to derive greater utility from such availability, 
including decreased symptoms,43 despite relatively small 
extensions of life.
Looking forward, low-dose chest CT scans to screen for 
lung cancer in patients may be increasingly accepted as 
effective preventive care compared with radiographic 
screens.42 Access to insurance is likely to increase access to 
such advanced preventive care, although patterns of care 
utilization may not change substantially after insurance is 
gained.44
Even if there is no evidence of clinical effects of Medicare, 
there may be individual utility improvements from access to 
universal insurance among the near-elderly.20 Inadequate 
access to actuarially fair insurance prevents consumption 
smoothing. Unaffordable access to private coverage for 
uninsured newly ill near-elderly households may lead to 
severe household wealth shocks.45 Since the near-elderly are 
risk-averse and financially constrained, both of these non-
clinical effects matter.
In conclusion, this study of an important and common can-
cer suggests that insurance status is not substantively associ-
ated with differences neither in access, treatment type and 
delay, nor in outcomes around the time of Medicare eligibil-
ity. Although extending Medicare-like benefits to the unin-
sured and underinsured near-elderly may be justified on many 
grounds, our results suggest that for these serious diseases 
there would be no significant improvements in outcomes.
Appendix
Robustness Checks
We considered 3 potential threats to the robustness of our 
results. These hinged around (1) adequacy of the study’s 
power, whether (2) inclusion in the study was biased by 
potential nonrandom missingness, and whether (3) the diag-
nostic threshold for lung cancer was constant.
Study Power to Detect Cohort Differences
Given the general lack of significant differences found in this 
study, it is important to question the level of statistical power 
conferred by the cohort sizes. For the lung cancer cohort 
sizes of 2500 patients, pairwise comparisons of lung cancer 
treatment receipt could detect differences of 3.5% points 
with 80% power, and similarly 3.5% point differences in sur-
vival, both at a specified type I error rate of 5%.
To put the latter difference into context, the death rate at 
24 months was almost 70%. Our 3.5% point detectable dif-
ference thus corresponds to a relative difference of approxi-
mately 5% between the cohorts. The results of Card et 
al15show a 20% relative reduction in deaths for severely ill 
patients treated urgently immediately after the age of 65 
years, compared with similar patients treated immediately 
before the age of 65 years, a mortality gap that persisted for 
at least 9 months after the index admission. Relative differ-
ences of such large magnitude could confidently be ruled out 
by our results for lung cancer.
Lung Cancer Pre-Medicare Cohort Nonrandom 
Missingness
A major concern with our use of SEER*Medicare data for 
lung cancer analyses is that participation in the study is condi-
tioned on survival to Medicare eligibility. That is, patients who 
succumb to their disease (whether diagnosed or not) before 
reaching the age of 65 years are not ascertained by NCI.
If substantial numbers of patients are missing not at random 
from the pre-eligible cohort of patients diagnosed at age 64.5 to 
65 years, then a potential bias to the null of no differences could 
exist. On average, patients in this age group have to survive 3 
months to be eligible for Medicare, while facing a mortality risk 
of approximately 25% over 3 months after diagnosis. Thus, it is 
potentially possible that many patients could die before ascer-
tainment, although the similarities in demographics between 
earlier and later cohorts militate against this explanation.
If such lack of ascertainment occurred, it is theoretically 
possible that the distribution of observed disease severity 
would be truncated from above in this cohort as more seri-
ous, more advanced cases died before ascertainment. 
However, we saw no evidence of such stage migration.
To understand this better, we examined cohort member-
ship by age in months. Overall, there is a smooth increase up 
to age 65 years (Figure A1). In the 18 months’ window of 
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Figure A1. Complete distribution of lung cancer cohort sizes, by age in months.
Note. Vertical line at 780 months corresponds to 65 years of age.
Figure A2. Lung cancer cohort sizes, by age in months around 65th year of age.
patient ages before the 64.5 to 65 years cohort, there is a 
steady upward trend, consistent with a biological increase in 
incidence and without substantial attrition (Figure A2). In the 
crucial 64.5 to 65 years cohort, no sharp fall off is seen. 
Instead, an increase in each month of age of around 100 
patients is seen. The size of final month in this cohort, cor-
responding to a patient aged 64 years 11 months, remains 
consistent with the longer trend. Over the 24 months’ win-
dow examined, it appears that cohort size is reasonably con-
stant. We believe this provides some reassurance that lack of 
ascertainment is not biasing our results from finding differ-
ences between the cohorts.
Lung Cancer Cohort Dependence on Diagnostic 
Threshold Stability
A further limitation is that we assumed that there was no 
change in diagnostic thresholds such as screening after the 
age of 65 years.46 If this is incorrect, then the possibility 
of stage migration biases exists.47 An asymptomatic 
patient with access to Medicare may procure a chest x-ray 
or CT chest due to concerns about prior smoking during 
the patient’s “welcome to Medicare” physical which is 
covered in the first 12 months after obtaining Part B 
coverage.
10 INQUIRY 
Such hypothetical Medicare-induced increased detection 
was, however, not found in our analysis, and the positive results 
found by Aberle and colleagues42 on low-dose CT screening 
for lung cancer did not come out till well after our cohort.
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